Clinical trials: Respiratory Tract Neoplasms
Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04267237
- Testing
- Atezolizumab, RO7198457
- Sponsor
- Hoffmann-La Roche
NSCLC, Stage III
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer…
- Trial name
- NCT05386888
- Testing
- GFH018, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non-Small Cell Lung Cancer
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Part 1 is complete. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, phase 2 segment that will commence upon identification of the maximum tolerated dose in part 1.
- Trial name
- NCT00534027
- Testing
- AMG 655
- Volunteers
- 172 people
- Sponsor
- Amgen
Advanced Malignancies, Non-small-cell Lung Cancer
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
- Trial name
- NCT04181788
- Testing
- PF-06801591
- Where
- 49 sites in China, Japan and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT00994123
- Testing
- MM-121, Erlotinib
- Where
- 38 sites in United States, Canada and 4 more
- Volunteers
- 162 people
- Sponsor
- Merrimack Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.
- Trial name
- NCT00870870
- Testing
- Gemcitabine, Cisplatin, IMC-A12 (cixutumumab)
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
The overall purpose of this phase II trial was to evaluate the efficacy of 250 mg BIBF 1120 twice daily (BID) versus 150 mg BIBF 1120 BID in patients with advanced non-small-cell lung cancer (NSCLC) who had failed at least one…
- Trial name
- NCT02182050
- Testing
- BIBF 1120 ES low dose, BIBF 1120 ES high dose
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study with a 1:1 randomization scheme.
- Trial name
- NCT01186861
- Testing
- OSI-906, erlotinib
- Where
- 69 sites in United States, Brazil and 7 more
- Volunteers
- 205 people
- Sponsor
- Astellas Pharma Inc
Neoplasm Metastasis, Brain Neoplasms
Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
The primary purpose of the study is to evaluate if motexafin gadolinium with whole brain radiation therapy followed by a stereotactic radiosurgery boost is a safe and effective treatment.
- Trial name
- NCT00121420
- Testing
- Motexafin gadolinium
- Where
- 12 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Pharmacyclics LLC.
Breast Cancer, Colorectal Cancer
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- GBCPRT0008 (NCT01792882)
- Where
- United States
- Sponsor
- Global BioClinical
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
This is a retrospective observational, open label study to evaluate and prospectively validate in a blind manner the accuracy of predicting treatment outcomes by PrediCare in individual patients with Non-Small Cell Lung Cancer…
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT02577627
- Testing
- PrediCare
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- Optimata Ltd.
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Metastatic Non-small Cell Lung Cancer
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to…
- Trial name
- NCT00806286
- Testing
- CS7017 tablets, Paclitaxel, Carboplatin
- Where
- 28 sites in United States, India and 2 more
- Volunteers
- 111 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Head and Neck Cancer
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced…
- Trial name
- NCT06056310
- Testing
- Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 18 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Small Cell Lung Cancer Extensive Stage
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06954246
- Testing
- MHB088C for Injection, Topotecan, Irinotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms, Carcinoma, Hepatocellular
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of…
- Conditions
- Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
- Trial name
- NCT06687941
- Testing
- AST-201
- Where
- 4 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Aptamer Sciences, Inc.
Advanced Non-squamous NSCLC
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with…
- Trial name
- NCT00369070
- Testing
- Bevacizumab, AMG 706, Paclitaxel
- Volunteers
- 186 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.